The Europe diabetic foot ulcer treatment market size is calculated at USD 1.52 billion in 2025 and is predicted to attain around USD 2.7 billion by 2035, expanding at a CAGR of 5.9% from 2026 to 2035. The market is observed to expand rapidly due to the growing prevalence of diabetes in the region, higher availability of wound dressing products, and the growing geriatric population.

Europe Diabetic Foot Ulcer Treatment Market Statical Scope

The Europe diabetic foot ulcer treatment market is expected to grow due to a rapid shift of the market towards advanced therapies such as bio-engineered skin substitutes , growth factors, and negative pressure wound therapy. Biologics, helpful for superior healing outcomes, are also a major market driver.

Europe Diabetic Foot Ulcer Treatment Market Share, By Treatment, 2025, (%)

• Wound Care Dressings- The segment accounts for 38% of the market share and is majorly driven by its contribution in managing and healing diabetic foot ulcers in the form of protection, moisture control, and infection prevention.
• Biologics- The segment holds 28% of the market share as it provides an advanced solution for ulcer healing, inclusive of growth factors and regenerative treatments.
• Therapy Devices- The segment holds 22% of the market share as it provides non-invasive treatment options such as electrical stimulation and negative pressure therapy.

Europe Diabetic Foot Ulcer Treatment Market Share, By Ulcer Type, 2025, (%)

• Neuropathic Ulcers- The segment accounts 42% of the market share, as it is stated as one of the most common forms of diabetic foot ulcers due to diabetic neuropathy.
• Ischemic Ulcers- The segment has 23% of the market share due to poor blood circulation in diabetic patients.
• Neuro-ischemic Ulcers- The segment has a notable share of 35% in the market, and it represents a combination of neuropathic and ischemic factors, making the treatment procedure a complex one.

Europe Diabetic Foot Ulcer Treatment Market Share, By End Use, 2025, (%)

• Hospitals- The segment has 48% of the market share, as the segment focuses on comprehensive care provided by hospitals for treating severe diabetic foot ulcers and advanced wound care.
• Ambulatory Imaging Centers- The segment holds 12% of the market share as it focuses on providing diagnostic imaging to assess ulcer severity.
• Homecare- The segment holds a dominant position of 40% of the market share and is driven mainly due to higher demand for outpatient and home care services.

Top Companies in the Europe Diabetic Foot Ulcer Treatment Market

• ConvaTec, Group Plc
• Acelity L.P., Inc.
• 3M Health Care
• Coloplast Corp.
• Smith & Nephew Plc
• B Braun Melsungen AG
• Medline Industries, LP.
• Molnlycke Health Care AB
• Medtronic Plc

Segments Covered in the Report

By Treatment

• Wound Care Dressings
• Biologics
• Therapy Devices
• Antibiotic Medications
• Others

By Ulcer Type

• Neuropathic Ulcers
• Ischemic Ulcers
• Neuro-ischemic Ulcers

By End Use

• Hospitals
• Ambulatory Imaging Centers
• Home Care